Home » Posts tagged 'investment' (Page 3)

Tag Archives: investment

#TM1 Technology Minerals PLC – Seven New Licences Secured at Leinster, Ireland

New prospecting licences expand the Company’s footprint to 760km2 at the Leinster lithium property in South East Ireland

 

Technology Minerals Plc (LSE: TM1), the first listed UK company focused on creating a sustainable circular economy for battery metals, is pleased to announce the addition of seven new prospecting licences to its ground holding on its Leinster Lithium Property, Republic of Ireland.  This addition brings the Company’s licence position to 23 licences covering a total of 760km2 of highly prospective geology with verified occurrences of spodumene-bearing lithium pegmatites. Initial reconnaissance at two localities on the new licences have already yielded two clusters of spodumene pegmatite float material with grades of up to 1.73% Li2O.

Highlights:

·    Seven new licences awarded to the Company’s 100% wholly owned subsidiary LRH Resources Limited.

·    The seven licences totalling 235km2 increase the overall ground holding to 760km2.

·    Two localities on the new licences reported historic spodumene-bearing lithium pegmatite occurrences (Irish Base Metals Report 1977).

·    A total of ten float samples were collected at two localities on Prospecting Licence Area (“PLA”) 3895 and PLA 3896.

·    Four samples on PLA 3895 yielded analyses of between 1.54 – 1.79 % Li2O.

·    Four samples on PLA 3896 yielded analyses of between 0.58 – 1.63 % Li2O.

·    The Company believes that the new licences lie on a parallel but less well-defined structural trend to the East Carlow Deformation Zone which itself has been shown to provide the locus for spodumene pegmatite emplacement.

·    The presence of structure is a key component to the anatectic genetic model for pegmatite development and emplacement in South East Ireland.

·    Follow up exploration will commence to further enhance understanding of the spatial distribution of the boulder trains discovered so far, as well as the rest of the licences.

 

New Licences

The seven licences, which were awarded to the Company’s wholly owned subsidiary LRH Resources Limited (“LRH”) on 1 December 2022, are 100% owned. The other 16 licences which form the rest of the Company’s Leinster Property exploration block, are operated under an exclusive Option and Earn-in agreement with Global Battery Metals Ltd (“GBML”), (TSXV: GBML; OTCQB: REZZF; Frankfurt: REZ).

 

The seven new licences form a contiguous block with the Company’s previously issued PLA 1597 and extends the ground holding both to the NE and SW of the Knockeen and Carriglead spodumene-bearing boulder trains which were reported on that licence. Together this block of eight licences form the Company’s South Leinster Block (Figure 1 & 2).

 

Project

Licence No.

County

Commencement
Date

Initial Duration

Area
Km
2

SW Leinster

1541

Wexford

01/12/2022

6-years

36.61

SW Leinster

1542

Wexford

01/12/2022

6-years

20.39

SW Leinster

3213

Kilkenny

01/12/2022

6-years

43.42

SW Leinster

3214

Kilkenny

01/12/2022

6-years

43.33

SW Leinster

3895

Wexford

01/12/2022

6-years

23.74

SW Leinster

3896

Wexford

01/12/2022

6-years

34.49

SW Leinster

4054

Wexford

01/12/2022

6-years

33.09

Total

235.07

Table 1: List of seven new licences issued December 2022

Geology and Preliminary Reconnaissance Sampling

The new licences are located along an interpreted NE-SW structural corridor which parallels both the SE margin of the Leinster Granite Batholiths as well as the associated East Carlow Deformation Zone (ECDZ) structural corridor. The ECDZ has provided a structural locus for a series of spodumene pegmatite occurrences which have been identified over 110km of extent between Dublin (and the Company’s Northern Block), and the Company’s Knockeen and Carriglead prospects on PLA 1597 to the south. The second structural corridor is interpreted to trend parallel and to the south of the ECDZ as it passes through the Company’s new licences.

Evidence for spodumene pegmatites relating to two historical boulder trains were reported in archive reports and maps at the Geological Survey of Ireland and date back to 1977. A brief reconnaissance visit to the two areas by the Company’s geologists on PLAs 3895 and 3896 have confirmed the presence of numerous boulders of spodumene pegmatite. Ten samples were collected for analysis during this initial reconnaissance visit.

 

The results of the sampling are presented below in Table 2 with the four samples on PLA 3895 returning assay values of between 1.54 – 1.79 % Li2O with four further samples on PL 3896 reporting between 0.58 – 1.63 % Li2O. Two further samples AES61135 and AES61136 comprising of altered lithologies associated with the pegmatites were also analysed (Table 2). The spatial distribution of the sampling across the two areas are presented in Figures 1-3 below. Ongoing geological mapping, and sampling by the Company will further define this zone and determine the full pegmatite prospectivity.

 

Project

Sample Type

Sample No

Licence

Li ppm

Li2O%

LRHR Leinster Project

Float

AES61127

3895

7260

1.56

LRHR Leinster Project

Float

AES61128

3895

7140

1.54

LRHR Leinster Project

Float

AES61129

3895

7990

1.72

LRHR Leinster Project

Float

AES61130

3895

8300

1.79

LRHR Leinster Project

Float

AES61131

3896

2700

0.58

LRHR Leinster Project

Float

AES61132

3896

5600

1.21

LRHR Leinster Project

Float

AES61133

3896

7570

1.63

LRHR Leinster Project

Float

AES61134

3896

4490

0.97

LRHR Leinster Project

Float

AES61135

3896

119

0.03

LRHR Leinster Project

Float

AES61136

3896

102

0.02

Table 2: Results from reconnaissance prospecting * Li2O % = Li % x 2.153

 

 Map Description automatically generated

Figure 1: Location of the company properties showing the Northern Block (15 licences)

and the Southern Block (eight licences)



Map Description automatically generated

Figure 2: Location of eight licences (seven new) comprising the Southern Block

Map Description automatically generated

Figure 3: Reconnaissance Sampling PLAs 3895 and 3896

 

Graphical user interface, application Description automatically generated

Photo 1: Spodumene pegmatite samples from PLA 3895: AES61127 (1.56% Li2O) and AES61129 (1.72% Li2O) and PLA 3896: AES61132 (1.21% Li2O)

 

 

Alex Stanbury, CEO of Technology Minerals, said: “We are pleased to add seven new prospecting licences to our Leinster Project, increasing our strategic foothold at the Leinster lithium property in South East Ireland by over 40 percent to 760km2. We consider these to be exciting additions to our portfolio and look forward to commencing further exploration to enhance our understanding of the project’s potential. Given the supply squeeze taking place for lithium globally, finding new sources of primary supply will be critical to help power the move to a carbon neutral economy.”

 

 

Competent Person

 

All scientific and technical information in this announcement has been prepared under the supervision of EuroGeol Vaughan Williams M.Sc. P.Geo (a Principal of Aurum Exploration Services who currently provides exploration services to TM and to LRH), and a “qualified person” within the meaning of National Instrument 43-101. Vaughan Williams is also company secretary of LRH and a Director of the LRH Spanish subsidiary Asturmet Recursos S.L.

 

 

Enquiries

Technology Minerals Plc

Robin Brundle, Executive Chairman

Alexander Stanbury, Chief Executive Officer

+44 20 4582 3500

Oberon Investments Limited

Nick Lovering, Adam Pollock

+44 (0)20 3179 0535

Arden Partners Plc

Tim Dainton, Louisa Waddell

+44 207 614 5900

Gracechurch Group

Harry Chathli, Alexis Gore, William Dobinson

+44 20 4582 3500

 

 

Technology Minerals Plc 

 

Technology Minerals is developing the UK’s first listed, sustainable circular economy for battery metals, using cutting-edge technology to recycle, recover, and re-use battery technologies for a renewable energy future. Technology Minerals is focused on extracting raw materials required for Li-ion batteries, whilst solving the ecological issue of spent Li-ion batteries, by recycling them for re-use by battery manufacturers. With the increasing global demand for battery metals to supply electrification, the group will explore, mine, and recycle metals from spent batteries. Further information on Technology Minerals is available at www.technologyminerals.co.uk  



Appendix 1: Analytical Results

Sample_ID

Programme

Li_ppm

Li2O%

Prospect

AES63003

Follow Up Sampling Dec 2022

17,410

3.75

Knockeen

AES63033

Follow Up Sampling Dec 2022

16,860

3.63

Knockeen

AES63519

Follow Up Sampling Dec 2022

13,160

2.83

Knockeen

AES63015

Follow Up Sampling Dec 2022

13,050

2.81

Knockeen

AES63029

Follow Up Sampling Dec 2022

12,920

2.78

Knockeen

AES63042

Follow Up Sampling Dec 2022

12,580

2.71

Knockeen

AES63014

Follow Up Sampling Dec 2022

12,200

2.63

Knockeen

AES63021

Follow Up Sampling Dec 2022

12,040

2.59

Knockeen

AES63018

Follow Up Sampling Dec 2022

11,980

2.58

Knockeen

AES63011

Follow Up Sampling Dec 2022

11,820

2.54

Knockeen

AES63023

Follow Up Sampling Dec 2022

11,620

2.50

Knockeen

AES63028

Follow Up Sampling Dec 2022

11,580

2.49

Knockeen

AES63041

Follow Up Sampling Dec 2022

11,570

2.49

Knockeen

AES63037

Follow Up Sampling Dec 2022

11,510

2.48

Knockeen

AES63016

Follow Up Sampling Dec 2022

11,460

2.47

Knockeen

AES63044

Follow Up Sampling Dec 2022

11,340

2.44

Knockeen

AES63012

Follow Up Sampling Dec 2022

11,180

2.41

Knockeen

AES63008

Follow Up Sampling Dec 2022

9,920

2.14

Knockeen

AES63048

Follow Up Sampling Dec 2022

9,520

2.05

Knockeen

AES63043

Follow Up Sampling Dec 2022

9,360

2.02

Knockeen

AES63027

Follow Up Sampling Dec 2022

8,820

1.90

Knockeen

AES63046

Follow Up Sampling Dec 2022

8,790

1.89

Knockeen

AES63516

Follow Up Sampling Dec 2022

8,370

1.80

Knockeen

AES63036

Follow Up Sampling Dec 2022

8,300

1.79

Knockeen

AES63007

Follow Up Sampling Dec 2022

8,090

1.74

Knockeen

AES63026

Follow Up Sampling Dec 2022

8,030

1.73

Knockeen

AES63010

Follow Up Sampling Dec 2022

7,890

1.70

Knockeen

AES63517

Follow Up Sampling Dec 2022

7,910

1.70

Knockeen

AES63512

Follow Up Sampling Dec 2022

7,840

1.69

Knockeen

AES63017

Follow Up Sampling Dec 2022

7,550

1.63

Knockeen

AES63520

Follow Up Sampling Dec 2022

7,370

1.59

Knockeen

AES63049

Follow Up Sampling Dec 2022

7,100

1.53

Knockeen

AES63515

Follow Up Sampling Dec 2022

7,040

1.52

Knockeen

AES63024

Follow Up Sampling Dec 2022

6,190

1.33

Knockeen

AES63031

Follow Up Sampling Dec 2022

6,140

1.32

Knockeen

AES63013

Follow Up Sampling Dec 2022

5,720

1.23

Knockeen

AES63019

Follow Up Sampling Dec 2022

5,420

1.17

Knockeen

AES63030

Follow Up Sampling Dec 2022

5,300

1.14

Knockeen

AES63034

Follow Up Sampling Dec 2022

4,960

1.07

Knockeen

AES63039

Follow Up Sampling Dec 2022

4,790

1.03

Knockeen

AES63022

Follow Up Sampling Dec 2022

4,710

1.01

Knockeen

AES63514

Follow Up Sampling Dec 2022

4,300

0.93

Knockeen

AES63045

Follow Up Sampling Dec 2022

4,290

0.92

Knockeen

AES63025

Follow Up Sampling Dec 2022

3,940

0.85

Knockeen

AES63032

Follow Up Sampling Dec 2022

3,550

0.76

Knockeen

AES63035

Follow Up Sampling Dec 2022

2,680

0.58

Knockeen

AES63009

Follow Up Sampling Dec 2022

1,920

0.41

Knockeen

AES63047

Follow Up Sampling Dec 2022

1,480

0.32

Knockeen

AES63038

Follow Up Sampling Dec 2022

450

0.10

Knockeen

AES63001

Follow Up Sampling Dec 2022

120

0.03

Knockeen

AES63002

Follow Up Sampling Dec 2022

120

0.03

Knockeen

AES63004

Follow Up Sampling Dec 2022

120

0.03

Knockeen

AES63005

Follow Up Sampling Dec 2022

130

0.03

Knockeen

AES63513

Follow Up Sampling Dec 2022

100

0.02

Knockeen

AES63518

Follow Up Sampling Dec 2022

80

0.02

Knockeen

AES63006

Follow Up Sampling Dec 2022

60

0.01

Knockeen

Table 4: Results from follow up prospecting at Knockeen (December 2022)

* Li2O % = Li ppm % (x 2.153)

 

Sample_ID

Programme

Li_ppm

Li2O%

Prospect

AES63504

Follow Up Sampling Dec 2022

9,720

2.09

Carriglead

AES63503

Follow Up Sampling Dec 2022

8,890

1.91

Carriglead

AES63509

Follow Up Sampling Dec 2022

7,870

1.69

Carriglead

AES63501

Follow Up Sampling Dec 2022

7,460

1.61

Carriglead

AES63507

Follow Up Sampling Dec 2022

5,620

1.21

Carriglead

AES63505

Follow Up Sampling Dec 2022

5,120

1.10

Carriglead

AES63508

Follow Up Sampling Dec 2022

3,280

0.71

Carriglead

AES63511

Follow Up Sampling Dec 2022

500

0.11

Carriglead

AES63506

Follow Up Sampling Dec 2022

330

0.07

Carriglead

AES63502

Follow Up Sampling Dec 2022

290

0.06

Carriglead

Table 5: Results from follow up prospecting at Carriglead (December 2022)

* Li2O % = Li ppm % (x 2.153)

#HVO hVIVO – Trading update

ImageEBITDA significantly ahead of expectations

Orderbook growth and improved operational delivery lays strong foundations for future growth

·    Record revenue, up 30% year-on-year to £50.6 million

·    EBITDA margins of no less than 17%, significantly ahead of guidance

·    Cash of £28.4 million as at 31 December 2022

·    Strong contracted orderbook of £76m, up 65% year-on-year

·    Board intention to declare shareholder distribution on publication of full audited accounts

·    Over 95% of 2023 revenue guidance contracted and visibility into 2024

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces a trading update for the period ended 31 December 2022.

 

Significant double-digit revenue growth

 

The Group expects to report record full year revenues of £50.6 million (2021: £39 million), a 30% increase year-on-year. The significant growth in revenue provides further validation of the long-term sustainable growth in the human challenge trial market, for which hVIVO is the world leader.

 

EBITDA margins and cash ahead of expectations

 

The Group expects to report EBITDA margins of not less than 17% (2021: 7.4%), significantly ahead of previous guidance of 13-15%. The increase in EBITDA is driven by strong trading in H2 2022 and operational efficiencies leveraged on the concurrent conduct of multiple challenge trials. In addition, recognition of postponement and cancellation fees for an aggregate of over £1 million had a one-time positive impact on EBITDA. The advanced fees from orderbook growth and efficient operational delivery has resulted in a cash position of £28.4 million as at 31 December 2022 (2021: £15.7 million).

 

Capital distribution

 

The Board intends to make a shareholder distribution in respect of the financial performance achieved in FY22, details of which will be announced alongside publication of the Group’s audited results for FY22. The distribution reflects the Group’s exceptional cash generation in the year, in addition to its robust balance sheet.

 

Further contracted orderbook growth enhances revenue visibility

 

In 2022, the trend of larger contracts with biopharma clients continued, increasing the size of the Group’s orderbook to £76 million as at 31 December 2022, up 65% year-on-year (2021: £46 million), and over sixfold since 2020 (2020: £12 million).

 

There has been increased demand for hVIVO’s unique full-service human challenge offering (with three contracts signed in 2022) which also involves the manufacture of bespoke challenge agents to test products against specific infectious disease variants, including subvariants that are circulating in the population. There has also been an increase in average challenge trial contract value driven by client demand for larger volunteer cohorts as the biopharma market increasingly recognises the value of human challenge data to accelerate drug development timelines and de-risk later stage clinical trial programmes.

 

Current year outlook

 

The Group has entered 2023 well capitalised, debt free, and with record visibility into the current financial year.  hVIVO is firmly placed to build on the growth in the human challenge trial market and further strengthen its position as the world leader in the field. The growing orderbook from new and existing Big Pharma and biotech clients provides excellent forward visibility with over 95% of forecasted revenue for 2023 contracted, and further revenue visibility into 2024. The Board is confident that the Group will continue to leverage its competitive position amidst favourable market dynamics and maintain its strong operational execution, orderbook revenue conversion and focus on profit generation into 2023 and beyond.

 

Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said: “The record numbers we have been able to announce today is the result of the hard work by everyone at hVIVO over the last 12 months. The goal for hVIVO has always been to establish a long-term sustainable growth model. We now have excellent profitable momentum, with full year 2022 EBITDA margin and cash significantly ahead of market expectations, while revenue shows substantial year-on-year growth. These results signify our successes of 2022 and also lay the foundations for FY23 and beyond. The record contracted orderbook not only covers over 95% of the FY23 revenue targets but also gives us visibility well into 2024.

 

“With the increasing prevalence and severity of infectious and respiratory diseases, there is a vital need for new vaccines and antivirals; as the human challenge partner of choice to the global biopharma industry, hVIVO is well placed to continue to help accelerate the development of these important new medicines.”

 

Investor presentation

 

Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation via the Investor Meet Company platform on 25 January 2023 at 18:00 BST.

 

The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and add to meet hVIVO here.

UK Investor Magazine Podcast- CEO Alan Green discusses Burberry, Argo Blockchain, and AB Dynamics

investor

Alan Green joins the Podcast as we discuss key market themes and a selection of UK equities.

We discuss:

  • Burberry (LON:BRBY)
  • Argo Blockchain (LON:ARB)
  • AB Dynamics (LON:ABDP)

UK inflation has began to fall and the FTSE 100 continues to flirt with all time highs. We look at what could derail a rally and the key influences on stocks.

Burberry has been a major beneficiary of Chinese economic expansion over the past 20 years. We run through this morning’s update as China reopens.

Argo Blockchain have secured financing to avoid a worst case scenario in the short term, we look at whether the recent jump in Argo shares is a dead cat bounce, or can be sustained.

We finish by looking at AB Dynamics.

#SVML Sovereign Metals Ltd – Issue of Unlisted Performance Rights

Sovereign Metals Limited (Sovereign or the Company) (ASX:SVM, AIM:SVML) advises that it has issued 1,560,000 Performance Rights to key employees and consultants as follows:

·      740,000 performance rights subject to the “Pre-Feasibility Study Milestone” expiring on 30 September 2023; and

·      820,000 performance rights subject to the “Feasibility Study Mine Milestone” expiring on 31 October 2025.

Following the issue of these Performance Rights, Sovereign has the following securities on issue:

·      470,875,023 ordinary fully paid shares;

·      11,105,125 unlisted options exercisable at A$0.80 each on or before 13 May 2023;

·      6,100,000 unlisted performance rights subject to the “Pre-Feasibility Study Milestone” expiring on 30 September 2023; and

·      8,260,000 unlisted performance rights subject to the “Feasibility Study Milestone” expiring on 31 October 2025.

ENQUIRIES

Dylan Browne
Company Secretary

+61(8) 9322 6322

#TEK Tekcapital PLC – Investee Company MicroSalt Partners with Hannaford Brothers

 

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Hannaford Brothers one of the most respected food retailers in the north-eastern United States has agreed to stock both sizes of MicroSalt’s new table-top shakers.

 

A person cooking in a restaurant Description automatically generated with low confidence

 

MicroSalt® provides a much-needed option that allows food manufacturers and consumers to slash the sodium content of their food without impacting the flavour. With 31% of adults worldwide suffering from high blood pressure and other cardiovascular diseases – and with efforts mounting around the globe to lower the sodium content in prepared and packaged foods – MicroSalt® is offering a truly timely solution.

 

“We are extremely excited that Hannaford Brothers has joined with us to provide low sodium solutions to its customers. This is a tremendous step in our march toward reducing excess sodium in the average diet. Our take-home shakers will let people salt their food to taste without excess sodium,” said Rick Guiney, CEO of MicroSalt®.

 

About Hannaford Supermarkets

Hannaford Supermarkets operates 185 stores in the Northeast, most with full-service pharmacies. Stores are located in Maine, New York, Massachusetts, New Hampshire, and Vermont. All are committed to offering great fresh food, convenient experiences and everyday low prices. Hannaford also is an active and committed community partner-focusing on fighting hunger, supporting youth development, and helping people live healthier lives. Hannaford is an industry leader in sustainability with a strong commitment to reducing waste and protecting the environment. Hannaford diverts or donates all food at risk of going to waste-sending no food to landfills. In 2020, Hannaford donated more than 25 million pounds of food to hunger relief organizations and prevented 65 million pounds of food waste from reaching landfills. Hannaford employs nearly 30,000 associates and is based in Scarborough, Maine. Additional information can be found at www.hannaford.com.

 

About MicroSalt®

MicroSalt, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples’ lives with better-for-you seasonings and snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavour because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.

 

To learn more about MicroSalt please visit https://www.microsaltinc.com

 

Tekcapital owns 97.2% of the share capital of MicroSalt Ltd. and 73% of MicroSalt Inc. its U.S. subsidiary.  

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

 

For further information, please contact:

Tekcapital Plc 

Via Flagstaff IR

Clifford M. Gross, Ph.D. 

SP Angel  Corporate Finance LLP                                                         (Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison / Charlie Bouverat (Corporate Finance)

Rob Rees (Corporate Broking)

 

 

Flagstaff Strategic and Investor Communications                                    +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon        

#TEK TEKCAPITAL PLC – NOMAD and Broker appointed for MicroSalt AIM IPO

Portfolio Company Update: MicroSalt, Ltd. (“MicroSalt”)

Appointment of Nominated Adviser and Broker for Proposed AIM IPO

 

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Zeus Capital Limited (“Zeus”) has been appointed by portfolio company MicroSalt as its Nominated Adviser and Broker for its proposed IPO on the AIM Market in 2023.

 

“We are very pleased to appoint Zeus as our Nominated Adviser and Broker, to assist MicroSalt in effectuating an AIM listing and to provide capital market guidance for our global growth strategy,” said Rick Guiney, CEO of MicroSalt®.

 

About MicroSalt®

MicroSalt, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples’ lives with better-for-you seasonings and snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavour because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.

 

To learn more about MicroSalt please visit https://www.microsaltinc.com

 

Tekcapital owns approximately 97% of the share capital of MicroSalt Ltd. and approximately 73% of MicroSalt Inc. its U.S. subsidiary.  

 

About Tekcapital plc

Tekcapital creates value by investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

For Further Information please contact:

 

Tekcapital Plc 

Via Flagstaff

Clifford M. Gross, Ph.D. 

SP Angel Corporate Finance LLP

(Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison/Charlie Bouverat (Corporate Finance)

Abigail Wayne/Rob Rees (Corporate Broking)

 

 

Flagstaff Strategic and Investor Communications

           

+44 (0) 20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

 

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving MicroSalt that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of MicroSalt’s and/or Tekcapital’s management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of MicroSalt or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither MicroSalt nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

#HVO hVIVO plc – Investors’ Chronicle

Building on decades of experiencehVIVO is currently the only CRO focused on challenge studiesproviding world class expertise and capabilities in challenge agent manufacturea unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease productsand specialist drug development and clinical consultancy services through its Venn Life Sciences subsidiary.

hVIVO contract awards Since the release of interim results in early SeptemberhVIVO has announced a massive £13.4mn contract with a US biotechnology clienta repeat customerto test its respiratory syncytial virus antiviral candidate using hVIVO’s established RSV Human Challenge Study Model.

Although difficult to assess the challenge study marketLiberum Capital estimates there are around 20 challenge studies conducted each year.

Using the prevailing average contract size of £6.7mnthis indicates £100mn-£135mn of challenge study work each yearexcluding any additional income through manufacturing and validating bespoke challenge agent.

Around 60 per cent of hVIVO’s current order book relates to biotech customers and the balance relates to big pharmawith the group carrying out three active challenge studies for big pharma in the first half of 2022 and two full-service challenge studies with values exceeding £25mn. MoreoverhVIVO has signed up eight challenge studies with big pharma companies since 201812  and all the big pharma clients are repeat customers.

Improving financials Backed by a bumper order book and having booked £9mn of group revenue in July and August 2022house broker FinnCap expects the group’s hVIVO divisionwhich carries out the challenge studiesto grow revenue from £29.4mn last year to £42.5mn in 2022 and account for 82 per cent of its total revenue estimate of £51.1mn. Furthermoretaking account of challenge study contract winsrevenue from Venn Lifelaboratory services and non-challenge studiesthe brokerage estimates that £53mn of its 2023 revenue estimate of £56mn is already covered.

SGS’s expertise is in performing influenza challenge studiesbut it also has Malaria challengeand RSV challenge models.

#TEK Tekcapital Plc – Appointment to the Board of MicroSalt

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Judith Batchelar OBE has joined the board of MicroSalt.

 

 

Judith currently serves as Deputy Chair of the U.K. Environment Agency, sits on UK Research and Innovation’s Natural Environment Research Council and is a Trustee of the Royal Botanic Gardens Kew. She has worked in the food and drink industry for over 35 years. From 2004 to 2021, she worked for Sainsbury’s as Director of Sainsbury’s Brand with responsibility for all aspects of Sainsbury’s product offer.

 

Prior to Sainsbury’s, Judith held a similar role at Safeway, spent twelve years in the Food Division at Marks & Spencer, and prior to this worked in manufacturing for Mars and Bass.

 

Judith is a biochemist and a nutritionist, has an Honorary Doctorate in Agriculture from Harper Adams University, and is a Fellow of the Institute of Food Science and Technology (IFST), and the Royal Society of Arts and Manufactures (RSA).

 

Judith was awarded an OBE in 2015 for services to Farming and the Food Industry, and serves on the Food, Farming and Countryside Commission.

 

“We are very excited to have Judith join our team. Her deep industry experience in improving the nutritional profile of foods will be enormously helpful with our go-to-market efforts in the U.K.,” said Rick Guiney, CEO of MicroSalt®.

 

Commenting on her appointment Judith Batchelar said, “I’m really excited to join the board of MicroSalt, I am passionate about their mission to help combat cardiovascular disease by reducing sodium levels in the foods we eat, and I know we can make a difference. “

 

About MicroSalt®

MicroSalt, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples’ lives with better-for-you seasonings and snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavour because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.

 

To learn more about MicroSalt please visit https://www.microsaltinc.com

 

Tekcapital owns 97.2% of the share capital of MicroSalt Ltd. and 73% of MicroSalt Inc. its U.S. subsidiary.  

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

 

For further information, please contact:

Tekcapital Plc 

Via Flagstaff IR

Clifford M. Gross, Ph.D. 

SP Angel  Corporate Finance LLP                                                         (Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison / Charlie Bouverat (Corporate Finance)

Rob Rees (Corporate Broking)

 

 

Flagstaff Strategic and Investor Communications                                    +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon   

#KAV Kavango Resources Plc- Strategic Financing to raise £3million

Kavango Resources plc (LSE:KAV), the exploration company targeting the discovery of world-class mineral deposits in Botswana, is pleased to announce that it has conditionally raised £3,000,000 before expenses by the issue of 166,666,660 New Ordinary Shares in the capital of the Company (“New Ordinary Shares”) at a price per share of 1.8 pence.

Fundraising

The 158,555,555 New Ordinary Shares have been conditionally placed by First Equity Limited (“First Equity”), on behalf of the Company with institutional and other investors, including high net worth and retail investors (the “Placing”).

The Placing includes one strategic cornerstone investor, who subscribed for over half of the Placing amount.

In addition to the Placing, the Company has also conditionally completed a direct subscription (the “Subscription”) for the issue of 8,111,105 New Ordinary Shares. 

Each New Ordinary Share has, on a one-for-one basis, a warrant attached exercisable at 3p for a term of 24 months from the date of issue. Issue of the warrants will require the approval of shareholders and details of a general meeting at which such approval will be sought will be sent to shareholders in the near future.

Further details of the Placing and Subscription, including the expected date of admission of the New Ordinary Shares (“Admission”), will be set out in a prospectus (“Prospectus”) to be published in electronic form and available on the Company’s website.

Ben Turney, Chief Executive Officer of Kavango, commented:

I am delighted to announce the successful completion of this £3million fund raising for Kavango, a transformational financing for the Company. 

Supported by many existing shareholders and new investors, we are now empowered to drive forward a dramatic exploration programme across our portfolio. Our current key focus is on our Kalahari Copper Belt interests, where the drilling programme is underway.

We are now fully funded for our ambitious plans through 2023 and are in an excellent position to achieve our goal of becoming the leading minerals exploration company in Botswana.”

Use of funds

The Placing and Subscription are to raise funds to meet exploration costs across the Company’s portfolio of projects in Botswana, and general working capital as set out below.

Funds raised from the Placing and Subscription will primarily be used to carry out proposed exploration work, provide working capital to the Group and to meet its regulatory and administrative commitments. 

Details of the Placing and Subscription

The New Ordinary Shares will represent approximately 27.7per cent. of the Enlarged Share Capital. The New Ordinary Shares will rank pari passu in all respects with Existing Ordinary Shares including all rights to dividends and other distributions declared, made or paid following Admission and will be issued as fully paid.  Application will be made for the New Ordinary Shares to be admitted to the Standard Segment of the Official List and to the London Stock Exchange. The Placing and Subscription are conditional, inter alia, on the approval of a Prospectus in relation to the Placing and Subscription Shares no later than 12 December 2022, or such later date as the Company and First Equity may agree.

In connection with the Placing, the Company shall issue

Subject to the approval of shareholders, one warrant will also be issued for each New Ordinary Share subscribed for at an exercise price of 3p for a period of thirty months from issue (“Financing Warrants”). Shareholder approval will be sought to the issue of the Financing Warrants in due course.

Total Voting Rights 

Following the issue of the Placing and Subscription Shares, the Company will have 602,312,586 Ordinary Shares in issue.

Prospectus

The Company is in process of seeking approval from the Financial Conduct Authority for its prospectus to be issued in connection with the Placing and Subscription. 

Further information in respect of the Company and its business interests is provided on the Company’s website at www.kavangoresources.com and on Twitter at #KAV.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (“UK MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Further information in respect of the Company and its business interests is provided on the Company’s website at www.kavangoresources.com and on Twitter at #KAV.

For further information please contact:

Kavango Resources plc                                                                                     

Ben Turney

bturney@kavangoresources.com

+46 7697 406 06

First Equity (Joint Broker)

+44 207 374 2212

Jason Robertson              

SI Capital Limited (Joint Broker)                                                                          

+44 1483 413500

Nick Emerson

#POLB Poolbeg Pharma PLC – Upcoming Events

21 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, announces that its management and business development team will be attending and presenting at a number upcoming partnering and investor events from October 2022 to January 2023.

 

Partnering events

BIO-Europe from 24-26 October 2022 at Leipzig Messe, Leipzig, Germany 04356

Jefferies London Healthcare Conference from 15-17 November 2022 in London

JP Morgan 41st Annual Healthcare Conference from 9-12 January 2023 at the Westin St. Francis Hotel, San Francisco, CA

 

Investor events

London South East Webinar (virtual) on 8 November 2022. Register here

LSX Inv€$tival ShowcaseTM on 14 November 2022 at Old Billingsgate, London EC3R 6DX. Poolbeg CEO, Jeremy Skillington, will present at 14:15 on Stage 4: Biotech Late Growth. Register here

 

Event details may be subject to change – further information and updates are available on the Poolbeg Pharma website here.

– Ends –

Enquiries

 

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

 

 +44 (0) 20 7183 1499

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, James Thompson, Charlie Beeson

Nigel Birks, Harriet Ward (ECM)

 

+44 (0) 20 7220 0500

Singer Capital Markets (Joint Broker)

Phil Davies, Sam Butcher

 

+44 (0) 20 7496 3000

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

+353 (0) 1 679 6363

Instinctif Partners

Melanie Toyne Sewell, Rozi Morris, Tim Field

 

+44 (0) 20 7457 2020

poolbeg@instinctif.com

 

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for pharma and biotech seeking mid-stage products to license or acquire.

 

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

 

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end 2022. 

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.